Comment on Komé et al. One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Works matching DE "SEMAGLUTIDE"
Results: 523
1
2
Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2025, v. 62, n. 1, p. 77, doi. 10.1111/apt.70190
- By:
- Publication type:
- Article
3
'We Have Work to Do': No Weight Loss Benefit With Semaglutide Before Bariatric Surgery.
- Published in:
- Healio Gastroenterology, 2025, v. 11, n. 5, p. 23
- By:
- Publication type:
- Article
4
High Discontinuation Rates of GLP-1 RA-Based Drugs Linked to Weight Loss Far Below Phase 3 Clinical Trials.
- Published in:
- Patient Care (Online), 2025, p. N.PAG
- By:
- Publication type:
- Article
5
Comparação indireta da sibutramina versus semaglutida para o tratamento da obesidade: uma revisão integrativa.
- Published in:
- Scire Salutis, 2024, v. 14, n. 3, p. 31, doi. 10.6008/CBPC2236-9600.2024.003.0003
- By:
- Publication type:
- Article
6
Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 7, p. 3757, doi. 10.1111/dom.16401
- By:
- Publication type:
- Article
7
Regeneron Phase 2b Study Shows Antibodies Help Preserve Lean Mass During Weight Loss with Semaglutide.
- Published in:
- Patient Care (Online), 2025, p. N.PAG
- By:
- Publication type:
- Article
8
The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems.
- Published in:
- Issues in Science & Technology, 2025, v. 41, n. 3, p. 24, doi. 10.58875/teqc7966
- By:
- Publication type:
- Article
9
The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort.
- Published in:
- Biomedicines, 2025, v. 13, n. 5, p. 1049, doi. 10.3390/biomedicines13051049
- By:
- Publication type:
- Article
10
Semaglutide and High-Intensity Interval Exercise Attenuate Cognitive Impairment in Type 2 Diabetic Mice via BDNF Modulation.
- Published in:
- Brain Sciences (2076-3425), 2025, v. 15, n. 5, p. 480, doi. 10.3390/brainsci15050480
- By:
- Publication type:
- Article
11
Real‐World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland.
- Published in:
- Journal of Diabetes, 2025, v. 17, n. 5, p. 1, doi. 10.1111/1753-0407.70102
- By:
- Publication type:
- Article
12
Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Published in:
- Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1438318
- By:
- Publication type:
- Article
13
Semaglutide Linked to Reduced Risk for MACE Months Before Weight Loss Begins: Post Hoc Analysis.
- Published in:
- Patient Care (Online), 2025, p. N.PAG
- By:
- Publication type:
- Article
14
A Half Dose of Semaglutide Yields Weight Loss Equivalent to Clinical Trial Doses in Combination with Online Support Program.
- Published in:
- Patient Care (Online), 2025, p. N.PAG
- By:
- Publication type:
- Article
15
Tirzepatide Demonstrates Greater Weight Loss Than Semaglutide in Head-to-Head Study.
- Published in:
- 2025
- By:
- Publication type:
- Abstract
16
Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose.
- Published in:
- Patient Care (Online), 2025, p. N.PAG
- By:
- Publication type:
- Article
17
FDA, Novo Nordisk Investigating Counterfeit Semaglutide Injection in US Supply Chain.
- Published in:
- Patient Care (Online), 2025, p. N.PAG
- By:
- Publication type:
- Article
18
Navigating GLP-1 Medication Access: Coverage Challenges, Emerging Cash-Pay Options.
- Published in:
- Patient Care (Online), 2025, p. N.PAG
- By:
- Publication type:
- Article
19
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study.
- Published in:
- Patient Care (Online), 2025, p. N.PAG
- By:
- Publication type:
- Article
20
Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits.
- Published in:
- Patient Care (Online), 2025, p. N.PAG
- By:
- Publication type:
- Article
21
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose.
- Published in:
- Patient Care (Online), 2025, p. 4
- By:
- Publication type:
- Article
22
High-Dose Semaglutide Linked to Increased Weight Loss: Daily Dose.
- Published in:
- Patient Care (Online), 2025, p. 3
- By:
- Publication type:
- Article
23
FDA Approves New Indication for Semaglutide (Ozempic) to Lower Kidney Risks in Type 2 Diabetes, CKD.
- Published in:
- Patient Care (Online), 2025, p. 2
- By:
- Publication type:
- Article
24
CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected.
- Published in:
- Patient Care (Online), 2024, p. 13
- By:
- Publication type:
- Article
25
Future of Obesity Care: 3 Wishes from Thought Leader Donna Ryan, MD.
- Published in:
- Patient Care (Online), 2024, p. 6
- By:
- Publication type:
- Article
26
Tirzepatide Superior to Semaglutide in Weight Loss Trial: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 7
- By:
- Publication type:
- Article
27
Tirzepatide Bests Semaglutide for Weight Loss by 47% in Head-to-Head Trial.
- Published in:
- Patient Care (Online), 2024, p. 4
- By:
- Publication type:
- Article
28
Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
29
Semaglutide vs Tirzepatide for Weight Loss in Persons with Obesity: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 70
- By:
- Publication type:
- Article
30
Weight Loss with Tirzepatide Significantly Greater than with Semaglutide: New Data.
- Published in:
- Patient Care (Online), 2024, p. 48
- By:
- Publication type:
- Article
31
Semaglutide Sold Online without Prescription May Put Users at Risk for Fraud, Overdose.
- Published in:
- Patient Care (Online), 2024, p. 6
- By:
- Publication type:
- Article
32
FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
33
WHO Issues Medical Product Alert for Counterfeit Semaglutide.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
34
ADA 84th Scientific Sessions: 3 Studies Primary Care Clinicians Should Put on Their Radar.
- Published in:
- Patient Care (Online), 2024, p. 3
- By:
- Publication type:
- Article
35
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Death in Persons with CKD, T2D: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 2
- By:
- Publication type:
- Article
36
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Mortality in People with CKD, T2D in Final FLOW Trial Findings.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
37
Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
38
Adults with Prior Antiobesity Medication Use Before Semaglutide Use Lose More Weight: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 2
- Publication type:
- Article
39
Adults with Obesity Who Receive Semaglutide as First Weight Loss Medication Lose More Weight.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
40
Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
41
Medicare Will Cover AOM Semaglutide for Cardiovascular Risk Reduction: A First.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
42
Semaglutide Lowers CKD-Related Events in Persons with T2D, CKD: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 2
- By:
- Publication type:
- Article
43
Semaglutide 2.4 mg (Wegovy) Wins Expanded Indication to Include Reduced Risk of MACE.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
44
Semaglutide Lowers CKD-Related Events in Persons with T2D, CKD: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
45
Semaglutide Shows Potential for Significant CVD Prevention: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
46
Semaglutide Reduces CKD-Related Events by 24% in Population with T2D and CKD: FLOW Findings Announced.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
47
Semaglutide Reduces CKD-Related Events by 24% in Population with T2D and CKD: FLOW Findings Announced.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
48
Where is All the Wegovy Going?
- Published in:
- Patient Care (Online), 2024, p. 2
- By:
- Publication type:
- Article
49
Semaglutide Linked to Lower Risk of Suicidal Ideation in Patients with Obesity, Type 2 Diabetes.
- Published in:
- Patient Care (Online), 2024, p. 3
- By:
- Publication type:
- Article
50
Semaglutide Shows Potential for Significant CVD Prevention in Analysis of Real-World Data.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article